The Mechanisms of the Roles of α-Synuclein, Amyloid-β, and Tau Protein in the Lewy Body Diseases: Pathogenesis, Early Detection, and Therapeutics
Moeko Noguchi‐Shinohara, Kenjiro Ono
Abstract
Lewy body diseases (LBD) are pathologically defined as the accumulation of Lewy bodies composed of an aggregation of α-synuclein (αSyn). In LBD, not only the sole aggregation of αSyn but also the co-aggregation of amyloidogenic proteins, such as amyloid-β (Aβ) and tau, has been reported. In this review, the pathophysiology of co-aggregation of αSyn, Aβ, and tau protein and the advancement in imaging and fluid biomarkers that can detect αSyn and co-occurring Aβ and/or tau pathologies are discussed. Additionally, the αSyn-targeted disease-modifying therapies in clinical trials are summarized.
Topics & Concepts
Lewy bodyProtein aggregationPathogenesisAlpha-synucleinAmyloid (mycology)Tau proteinDiseaseDementia with Lewy bodiesAmyloid βMedicineNeuroscienceParkinson's diseasePathologyChemistryAlzheimer's diseaseBiologyBiochemistryDementiaParkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatmentsGinkgo biloba and Cashew Applications